Genscript Biotech Stock Operating Margin

GNNSF Stock  USD 1.25  0.01  0.79%   
Genscript Biotech fundamentals help investors to digest information that contributes to Genscript Biotech's financial success or failures. It also enables traders to predict the movement of Genscript Pink Sheet. The fundamental analysis module provides a way to measure Genscript Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genscript Biotech pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Genscript Biotech Company Operating Margin Analysis

Genscript Biotech's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current Genscript Biotech Operating Margin

    
  (0.64) %  
Most of Genscript Biotech's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genscript Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, Genscript Biotech has an Operating Margin of -0.6413%. This is 98.17% lower than that of the Healthcare sector and 99.43% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 88.36% lower than that of the firm.

Genscript Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genscript Biotech's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genscript Biotech could also be used in its relative valuation, which is a method of valuing Genscript Biotech by comparing valuation metrics of similar companies.
Genscript Biotech is currently under evaluation in operating margin category among its peers.

Genscript Fundamentals

About Genscript Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Genscript Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genscript Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genscript Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Genscript Pink Sheet

Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.